Alkem Laboratories Limited (NSE:ALKEM)

Market Cap	650.43B +10.9%
Revenue (ttm)	142.53B +11.7%
Net Income	23.71B +10.1%
EPS	198.31 +10.1%
Shares Out	119.57M
PE Ratio	27.43
Forward PE	27.78
Dividend	45.00 (0.83%)
Ex-Dividend Date	Feb 20, 2026

Volume	165,463
Average Volume	125,691
Open	5,380.00
Previous Close	5,440.00
Day's Range	5,308.50 - 5,432.00
52-Week Range	4,716.20 - 5,933.50
Beta	0.32
RSI	49.73
Earnings Date	May 26, 2026

About Alkem Laboratories

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, r...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 18,785
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ALKEM

Financial Performance

In fiscal year 2025, Alkem Laboratories's revenue was 129.65 billion, an increase of 2.34% compared to the previous year's 126.68 billion. Earnings were 21.65 billion, an increase of 20.59%.